Formulation, Characterization and Optimization of β-Glucan and Pomegranate Juice Based Films for Its Potential in Diabetes

Nutrients. 2022 May 20;14(10):2142. doi: 10.3390/nu14102142.

Abstract

The aim of this study was to develop films based on β-glucans in association with pomegranate juice for its potential in metabolic disorders such as diabetes due to plenty of bioactive compounds from the film composition. Initially, a Box-Behnken design was generated by varying the level of β-glucan content (0.5, 1, 1.5 g), sodium alginate (0.2, 0.4, 0.6 g) and pomegranate juice (10, 20, 30 mL) for development of films. Subsequently, glycerin was added as 25% of the total dry matter. The optimization of the films prepared by the solvent casting method was conducted based on the different responses such as: water vapor transmission rate (WVTR), water vapor permeability (WVP), thickness, density, moisture content, solubility, film opacity and color. The water activity profile and FT-IR analysis were performed in all tests. The model was used to determine the optimal experimental values considering that the optimal film will make a sustained contribution to diabetes. The optimal values of the film sample made of β-glucans, sodium alginate, pomegranate juice and glycerin make it befitting for packaging dry powdered pharmaceuticals. Finally, antimicrobial activity against Gram-negative and Gram-positive bacteria, UV barrier properties and microcrack and pore detections through SEM were also investigated for the optimal film sample.

Keywords: bioactive films; diabetes; pomegranate juice; vasoprotective effects; β–glucan.

MeSH terms

  • Alginates
  • Diabetes Mellitus*
  • Glycerol
  • Pomegranate*
  • Spectroscopy, Fourier Transform Infrared
  • Steam
  • beta-Glucans*

Substances

  • Alginates
  • Steam
  • beta-Glucans
  • Glycerol

Grants and funding

This work was funded by Ministry of Research, Innovation and Digitalization within Program 1—Development of national research and development system, Subprogram 1.2—Institutional Performance—RDI excellence funding projects, under contract no. 10PFE/2021.